Dossier
Elevidys
Coverage of Elevidys in the Nexus archive.
- STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
Regenxbio's experimental gene therapy for Duchenne muscular dystrophy has produced high levels of a miniaturized muscle protein, paving the way for FDA submission. The company aims to create a safer and more effective therapy than Sarepta Therapeutics' Elevidys. Regenxbio is seeking accelerated approval.